المؤلفون: E Gazi, J Dwyer, P Gardner, A Ghanbari-Siahkali, AP Wade, J Miyan, NP Lockyer, JC Vickerman, NW Clarke, JH Shanks, LJ Scott, CA Hart, M Brown

المصدر: Journal of Pathology; Sep2003, Vol. 201 Issue 1, p99, 10p

مصطلحات موضوعية: FOURIER transform infrared spectroscopy, PROSTATE cancer, EXOCRINE glands, CANCER cells, CELLULAR pathology

المؤلفون: Cl, Vale, Burdett S, Lh, Rydzewska, Albiges L, Nw, Clarke, Fisher D, Fizazi K, Gravis G, Nd, James, Md, Mason, Mk, Parmar, Cj, Sweeney, Sydes MR, Tombal B, Jayne Tierney, STOpCaP Steering Group

المصدر: Europe PubMed Central

URL الوصول: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::4e330b3b76477b44d7aa3d345c3dec1f
http://europepmc.org/abstract/med/26718929

المؤلفون: Parry MG; Department of Health Services Research and Policy, The London School of Hygiene and Tropical Medicine (LSHTM), London, UK.; The National Prostate Cancer Audit, Clinical Effectiveness Unit, Royal College of Surgeons of England, London, UK., Sujenthiran A; The National Prostate Cancer Audit, Clinical Effectiveness Unit, Royal College of Surgeons of England, London, UK.; Flatiron, London, UK., Nossiter J; Department of Health Services Research and Policy, The London School of Hygiene and Tropical Medicine (LSHTM), London, UK.; The National Prostate Cancer Audit, Clinical Effectiveness Unit, Royal College of Surgeons of England, London, UK., Morris M; Department of Health Services Research and Policy, The London School of Hygiene and Tropical Medicine (LSHTM), London, UK.; The National Prostate Cancer Audit, Clinical Effectiveness Unit, Royal College of Surgeons of England, London, UK., Berry B; Department of Health Services Research and Policy, The London School of Hygiene and Tropical Medicine (LSHTM), London, UK.; The National Prostate Cancer Audit, Clinical Effectiveness Unit, Royal College of Surgeons of England, London, UK., Nathan A; The National Prostate Cancer Audit, Clinical Effectiveness Unit, Royal College of Surgeons of England, London, UK.; University College London, London, UK., Aggarwal A; Department of Health Services Research and Policy, The London School of Hygiene and Tropical Medicine (LSHTM), London, UK.; Department of Radiotherapy, Guy's and St Thomas' NHS Foundation Trust, London, UK., Payne H; Department of Oncology, University College London Hospitals, London, UK., van der Meulen J; Department of Health Services Research and Policy, The London School of Hygiene and Tropical Medicine (LSHTM), London, UK., Clarke NW; Department of Urology, The Christie and Salford Royal Hospitals, Manchester, UK.

المصدر: BJU international [BJU Int] 2024 Aug; Vol. 134 (2), pp. 313. Date of Electronic Publication: 2024 Mar 22.

نوع المنشور: Letter

بيانات الدورية: Publisher: Blackwell Science Country of Publication: England NLM ID: 100886721 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1464-410X (Electronic) Linking ISSN: 14644096 NLM ISO Abbreviation: BJU Int Subsets: MEDLINE

مواضيع طبية MeSH: Prostatic Neoplasms*/therapy, Humans ; Male ; Treatment Outcome ; Ultrasound, High-Intensity Focused, Transrectal

المؤلفون: Parker CC; Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Sutton, UK. Electronic address: chris.parker@rmh.nhs.uk., Petersen PM; Department of Oncology, Copenhagen Prostate Cancer Center, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark., Cook AD; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London., Clarke NW; Department of Urology, The Christie NHS Foundation Trust, Manchester; Manchester Cancer Research Centre, The University of Manchester, Manchester; Department of Urology, Salford Royal NHS Foundation Trust, Manchester, UK, Department of Urology, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK., Catton C; Department of Radiation Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada., Cross WR; Department of Urology, St James's University Hospital, Leeds., Kynaston H; Division of Cancer and Genetics, Cardiff University, Cardiff, UK., Parulekar WR; Canadian Cancer Trials Group, Queen's University, Kingston, Canada., Persad RA; Department of Urology, Bristol Urological Institute, Bristol, UK., Saad F; Department of Urology, Centre Hospitalier de l'Université de Montréal, Montreal, Canada., Bower L; Guy's and St Thomas' NHS Foundation Trust, London; Institute of Cancer Research, Royal Marsden NHS Foundation Trust, London, UK., Durkan GC; Department of Urology, University Hospital Galway, Galway, Ireland., Logue J; Department of Oncology, The Christie Hospital NHS FT, Wilmslow Road, Manchester., Maniatis C; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London., Noor D; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London., Payne H; The Prostate Centre, London., Anderson J; St James's Institute of Oncology, Leeds., Bahl AK; Bristol Haematology and Oncology Centre, University Hospitals Bristol & Weston NHS Trust, Bristol., Bashir F; Queen's Centre for Oncology, Castle Hill Hospital, Hull University Teaching Hospitals NHS Trust, Cottingham, UK., Bottomley DM; St James's Institute of Oncology, Leeds., Brasso K; Department of Urology, Copenhagen Prostate Cancer Center, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Capaldi L; Worcester Oncology Centre, Worcestershire Acute NHS Hospitals Trust, Worcester., Chung C; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London., Cooke PW; Department of Urology, The Royal Wolverhampton NHS Trust, Wolverhampton., Donohue JF; Department of Urology, Maidstone and Tunbridge Wells NHS Trust, Maidstone., Eddy B; East Kent University Hospitals Foundation Trust, Kent., Heath CM; Department of Clinical Oncology, University Hospital Southampton NHS Foundation Trust, Southampton., Henderson A; Department of Urology, Maidstone and Tunbridge Wells NHS Trust, Maidstone., Henry A; Leeds Institute of Medical Research, University of Leeds, Leeds., Jaganathan R; Department of Urology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK., Jakobsen H; Department of Urology, Herlev University Hospital, Herlev, Denmark., James ND; Institute of Cancer Research, Royal Marsden NHS Foundation Trust, London, UK., Joseph J; Leeds Teaching Hospitals; York and Scarborough Teaching Hospitals, York., Lees K; Kent Oncology Centre, Maidstone and Tunbridge Wells NHS Trust, Maidstone., Lester J; South West Wales Cancer Centre, Singleton Hospital, Swansea, UK., Lindberg H; Department of Oncology, Herlev University Hospital, Herlev, Denmark., Makar A; Department of Urology, Worcestershire Acute Hospitals Trust, Worcester., Morris SL; Guy's and St Thomas' NHS Foundation Trust, London., Oommen N; Wrexham Maelor Hospital, Wrexham., Ostler P; Department of Urology, Hillingdon Hospitals NHS Foundation Trust, Hillingdon, London., Owen L; Bradford Royal Infirmary, Bradford; Leeds Cancer Centre, Leeds., Patel P; Department of Urology, University College London Hospitals, London., Pope A; Department of Urology, Hillingdon Hospitals NHS Foundation Trust, Hillingdon, London., Popert R; Guy's and St Thomas' NHS Foundation Trust, London., Raman R; Kent Oncology Centre, Kent & Canterbury Hospital, Canterbury., Ramani V; Department of Urology, The Christie NHS Foundation Trust, Manchester., Røder A; Department of Urology, Copenhagen Prostate Cancer Center, Copenhagen University Hospital, Rigshospitalet, Copenhagen., Sayers I; Deanesly Centre, New Cross Hospital, Wolverhampton., Simms M; Department of Urology, Hull University Hospitals NHS Trust, Hull., Srinivasan V; Glan Clwyd Hospital, Betsi Cadwaladr University Health Board, Rhyl., Sundaram S; Department of Urology, Mid Yorkshire Teaching Hospital, Wakefield., Tarver KL; Department of Oncology, Queen's Hospital, Romford., Tran A; Department of Oncology, The Christie Hospital NHS FT, Wilmslow Road, Manchester., Wells P; Barts Cancer Centre, St Bartholomews Hospital, London., Wilson J; Royal Gwent Hospital, Newport., Zarkar AM; Department of Oncology, University Hospitals Birmingham, Birmingham, UK., Parmar MKB; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London., Sydes MR; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London. Electronic address: mrcctu.radicals@ucl.ac.uk.

مؤلفون مشاركون: RADICALS investigators

المصدر: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2024 Jul; Vol. 35 (7), pp. 656-666. Date of Electronic Publication: 2024 Apr 05.

نوع المنشور: Journal Article; Randomized Controlled Trial; Multicenter Study

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Prostatectomy*/methods , Prostatic Neoplasms*/radiotherapy , Prostatic Neoplasms*/surgery , Prostatic Neoplasms*/pathology , Salvage Therapy*/methods, Humans ; Male ; Aged ; Middle Aged ; Radiotherapy, Adjuvant/adverse effects ; Radiotherapy, Adjuvant/methods ; Prostate-Specific Antigen/blood ; Neoplasm Recurrence, Local/pathology ; Neoplasm Recurrence, Local/prevention & control ; Neoplasm Grading ; Time Factors

المؤلفون: Parker CC; The Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK., Clarke NW; Department of Urology, The Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, University of Manchester, Manchester, UK; Department of Urology, Salford Royal Hospital, Salford, UK., Cook AD; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Kynaston H; Division of Cancer and Genetics, Cardiff University Medical School, Cardiff, UK., Catton CN; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Cross WR; Department of Urology, St James's University Hospital, Leeds, UK., Petersen PM; Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Persad RA; Department of Urology, Bristol Urological Institute, Bristol, UK., Saad F; Department of Urology, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada., Bower LC; The Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK; Guy's and St Thomas' NHS Foundation Trust, London, UK., Logue J; Department of Urology, The Christie NHS Foundation Trust, Manchester, UK., Payne H; The Prostate Centre, London, UK., Forcat S; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Goldstein C; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Murphy C; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Anderson J; Department of Clinical Oncology, St James's University Hospital, Leeds, UK., Barkati M; Department of Radiation Oncology, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada., Bottomley DM; Department of Clinical Oncology, St James's University Hospital, Leeds, UK., Branagan J; Northampton General Hospital, Northampton, UK., Choudhury A; Department of Urology, The Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, University of Manchester, Manchester, UK., Chung PWM; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada., Cogley L; Derriford Hospital, Plymouth, UK., Goh CL; Royal Surrey Hospital, Guildford, UK., Hoskin P; Division of Cancer Sciences, University of Manchester, Manchester, UK; Mount Vernon Cancer Centre, Northwood, UK., Khoo V; The Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK., Malone SC; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada., Masters L; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Morris SL; Guy's and St Thomas' NHS Foundation Trust, London, UK., Nabid A; Service de Radio-Oncologie, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada., Ong AD; Max Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada., Raman R; Kent Oncology Centre, Kent and Canterbury Hospital, Canterbury, UK., Tarver KL; Department of Oncology, Queen's Hospital, Romford, UK., Tree AC; The Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK., Worlding J; University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK., Wylie JP; Department of Urology, The Christie NHS Foundation Trust, Manchester, UK., Zarkar AM; Department of Oncology, University Hospitals Birmingham, Birmingham, UK., Parulekar WR; Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada., Parmar MKB; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Sydes MR; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK. Electronic address: mrcctu.radicals@ucl.ac.uk.

مؤلفون مشاركون: RADICALS investigators

المصدر: Lancet (London, England) [Lancet] 2024 Jun 01; Vol. 403 (10442), pp. 2405-2415. Date of Electronic Publication: 2024 May 16.

نوع المنشور: Journal Article; Randomized Controlled Trial; Multicenter Study; Comparative Study

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE

مواضيع طبية MeSH: Prostatic Neoplasms*/pathology , Prostatic Neoplasms*/radiotherapy , Prostatic Neoplasms*/therapy , Prostatic Neoplasms*/drug therapy , Androgen Antagonists*/therapeutic use , Androgen Antagonists*/administration & dosage , Prostatectomy* , Tosyl Compounds*/therapeutic use , Tosyl Compounds*/administration & dosage , Anilides*/therapeutic use , Anilides*/administration & dosage , Nitriles*/therapeutic use , Nitriles*/administration & dosage, Humans ; Male ; Aged ; Middle Aged ; Oligopeptides/therapeutic use ; Oligopeptides/administration & dosage ; Gonadotropin-Releasing Hormone/agonists ; Combined Modality Therapy ; Prostate-Specific Antigen/blood

المؤلفون: Parker CC; The Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK., Kynaston H; Division of Cancer and Genetics, Cardiff University Medical School, Cardiff, UK., Cook AD; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Clarke NW; Department of Urology, The Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, University of Manchester, Manchester, UK; Department of Urology, Salford Royal Hospital, Salford, UK., Catton CN; Princess Margaret Cancer Centre, Toronto, ON, Canada., Cross WR; Department of Urology, St James's University Hospital, Leeds, UK., Petersen PM; Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Persad RA; Department of Urology, Bristol Urological Institute, Bristol, UK., Pugh CA; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Saad F; Department of Urology, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada., Logue J; Department of Urology, The Christie NHS Foundation Trust, Manchester, UK., Payne H; The Prostate Centre, London, UK., Bower LC; The Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK; Guy's and St Thomas' NHS Foundation Trust, London, UK., Brawley C; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Rauchenberger M; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Barkati M; Department of Radiation Oncology, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada., Bottomley DM; Department of Clinical Oncology, St James's University Hospital, Leeds, UK., Brasso K; Department of Urology, Copenhagen Prostate Cancer Center, Rigshospitalet, Copenhagen, Denmark., Chung HT; Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada., Chung PWM; Princess Margaret Cancer Centre, Toronto, ON, Canada; Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada., Conroy R; Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK., Falconer A; Radiotherapy Department, Charing Cross Hospital, London, UK., Ford V; Royal Devon and Exeter University NHS Foundation Trust, Exeter, UK., Goh CL; Royal Surrey County Hospital, Guildford, UK., Heath CM; Department of Clinical Oncology, University Hospital Southampton NHS Foundation Trust, Southampton, UK., James ND; The Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UK., Kim-Sing C; Department of Radiation Oncology, BC Cancer-Vancouver, Vancouver, BC, Canada., Kodavatiganti R; Glan Clwyd Hospital, Betsi Cadwaladr University Health Board, Bangor, UK., Malone SC; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada., Morris SL; Guy's and St Thomas' NHS Foundation Trust, London, UK., Nabid A; Service de Radio-Oncologie, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada., Ong AD; Max Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada., Raman R; Kent Oncology Centre, Kent and Canterbury Hospital, Canterbury, UK., Rodda S; Bradford Teaching Hospitals, Bradford, UK., Wells P; Barts Cancer Centre, St Bartholomew's Hospital, London, UK., Worlding J; University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK., Parulekar WR; Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada., Parmar MKB; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Sydes MR; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK. Electronic address: mrcctu.radicals@ucl.ac.uk.

مؤلفون مشاركون: RADICALS investigators

المصدر: Lancet (London, England) [Lancet] 2024 Jun 01; Vol. 403 (10442), pp. 2416-2425. Date of Electronic Publication: 2024 May 16.

نوع المنشور: Journal Article; Randomized Controlled Trial; Comparative Study; Multicenter Study

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE

مواضيع طبية MeSH: Prostatic Neoplasms*/pathology , Prostatic Neoplasms*/radiotherapy , Prostatic Neoplasms*/drug therapy , Prostatic Neoplasms*/therapy , Prostatic Neoplasms*/surgery , Androgen Antagonists*/therapeutic use , Androgen Antagonists*/administration & dosage , Prostatectomy* , Tosyl Compounds*/therapeutic use , Tosyl Compounds*/administration & dosage , Anilides*/therapeutic use , Anilides*/administration & dosage , Nitriles*/therapeutic use , Nitriles*/administration & dosage, Humans ; Male ; Aged ; Middle Aged ; Oligopeptides/administration & dosage ; Oligopeptides/therapeutic use ; Gonadotropin-Releasing Hormone/agonists ; Prostate-Specific Antigen/blood ; Combined Modality Therapy ; Drug Administration Schedule

المؤلفون: Saad F; Centre Hospitalier de l'Université de Montréal, Montreal, Canada. Electronic address: fred.saad@umontreal.ca., Del Rosario P; Global Medicines Development, Oncology R&D, AstraZeneca, Cambridge, UK., Clarke NW; The Christie and Salford Royal Hospital NHS Foundation Trusts and University of Manchester, Manchester, UK.

المصدر: European urology [Eur Urol] 2024 Jun; Vol. 85 (6), pp. e178-e179. Date of Electronic Publication: 2023 Dec 01.

نوع المنشور: Letter; Comment

بيانات الدورية: Publisher: Elsevier Science Country of Publication: Switzerland NLM ID: 7512719 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-7560 (Electronic) Linking ISSN: 03022838 NLM ISO Abbreviation: Eur Urol Subsets: MEDLINE

مواضيع طبية MeSH: Prostatic Neoplasms, Castration-Resistant*/drug therapy , Prostatic Neoplasms, Castration-Resistant*/pathology , Phthalazines*/therapeutic use , Androstenes*/therapeutic use , Piperazines*/therapeutic use, Humans ; Male ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Randomized Controlled Trials as Topic ; Double-Blind Method ; Clinical Trials, Phase III as Topic ; Neoplasm Metastasis

المؤلفون: Fankhauser CD; Department of Urology, University of Lucerne, Luzerner Kantonsspital, Lucerne, Switzerland; Department of Urology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. Electronic address: cdfankhauser@gmail.com., Wettstein MS; Princess Margaret Hospital, Toronto, Canada., Würnschimmel C; Department of Urology, University of Lucerne, Luzerner Kantonsspital, Lucerne, Switzerland., van Smeden M; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands., Clarke NW; The Christie and Salford Royal Hospital NHS Trusts, Manchester, UK; University of Manchester, Manchester, UK.

المصدر: European urology [Eur Urol] 2024 May 15. Date of Electronic Publication: 2024 May 15.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Science Country of Publication: Switzerland NLM ID: 7512719 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-7560 (Electronic) Linking ISSN: 03022838 NLM ISO Abbreviation: Eur Urol Subsets: MEDLINE

المؤلفون: Saad F; Centre Hospitalier de l'Université de Montréal/CRCHUM, Université de Montréal, Montreal, QC, Canada. Electronic address: fred.saad@umontreal.ca., Armstrong AJ; Duke Cancer Institute Center for Prostate and Urologic Cancer, Duke University, Durham, NC, USA., Oya M; Keio University School of Medicine, Tokyo, Japan., Vianna K; Centro Integrado de Oncologia de Curitiba, Curitiba, Brazil., Özgüroğlu M; Istanbul University Cerrahpaşa, Faculty of Medicine, Istanbul, Türkiye., Gedye C; Calvary Mater Newcastle, Waratah, NSW, Australia., Buchschacher GL Jr; Kaiser Permanente Southern California, Los Angeles, CA, USA., Lee JY; The Catholic University of Korea Seoul St Mary's Hospital, Seoul, South Korea., Emmenegger U; Sunnybrook Research Institute, Toronto, ON, Canada., Navratil J; Masaryk Memorial Cancer Institute, Brno, Czech Republic., Virizuela JA; Hospital Universitario Virgen Macarena, Sevilla, Spain., Salazar A; Instituto de Especialidades Urologicas, Santiago, Chile., Maillet D; Centre Hospitalier Lyon Sud, Pierre-Bénite, France; Faculté de Médecine Jacques Lisfranc, Saint-Etienne, France., Uemura H; Yokohama City University Medical Center, Kanagawa, Japan., Kim J; Merck & Co., Inc., Rahway, NJ, USA., Oscroft E; AstraZeneca, Cambridge, UK., Barker L; AstraZeneca, Cambridge, UK., Degboe A; AstraZeneca, Baltimore, MD, USA., Clarke NW; The Christie and Salford Royal Hospital NHS Foundation Trusts, and University of Manchester, Manchester, UK.

المصدر: European urology oncology [Eur Urol Oncol] 2024 Apr 05. Date of Electronic Publication: 2024 Apr 05.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101724904 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2588-9311 (Electronic) Linking ISSN: 25889311 NLM ISO Abbreviation: Eur Urol Oncol Subsets: MEDLINE

المؤلفون: Gilbert DC; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, London, UK; University Hospitals Sussex NHS Foundation Trust, Royal Sussex County Hospital, Brighton, UK. Electronic address: duncan.gilbert@ucl.ac.uk., Nankivell M; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, London, UK., Rush H; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, London, UK., Clarke NW; The Christie and Salford Royal Hospitals, Manchester, UK., Mangar S; Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK., Al-Hasso A; Beatson West of Scotland Cancer Centre, Glasgow, UK., Rosen S; National Heart and Lung Institute, Imperial College, London, UK., Kockelbergh R; Department of Urology, University Hospitals of Leicester, Leicester, UK., Sundaram SK; Mid-Yorkshire Teaching NHS Trust, Pinderfields Hospital, Wakefield, UK., Dixit S; Scunthorpe General Hospital, Scunthorpe, UK., Laniado M; Wexham Park Hospital, Slough, UK., McPhail N; Raigmore Hospital, Inverness, UK., Shaheen A; Singleton Hospital, Swansea, UK., Brown S; Airedale General Hospital, Keighley, UK., Gale J; Queen Alexandra Hospital, Portsmouth, UK., Deighan J; Patient Representative, MRC Clinical Trials Unit at UCL, London, UK., Marshall J; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, London, UK., Duong T; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, London, UK., Macnair A; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, London, UK; Guys and St Thomas' NHS Foundation Trust, London, UK., Griffiths A; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, London, UK., Amos CL; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, London, UK., Sydes MR; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, London, UK., James ND; Institute of Cancer Research, Sutton, UK., Parmar MKB; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, London, UK., Langley RE; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, London, UK.

المصدر: Clinical oncology (Royal College of Radiologists (Great Britain)) [Clin Oncol (R Coll Radiol)] 2024 Jan; Vol. 36 (1), pp. e11-e19. Date of Electronic Publication: 2023 Nov 08.

نوع المنشور: Clinical Trial, Phase II; Journal Article

بيانات الدورية: Publisher: W.B. Saunders Country of Publication: England NLM ID: 9002902 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1433-2981 (Electronic) Linking ISSN: 09366555 NLM ISO Abbreviation: Clin Oncol (R Coll Radiol) Subsets: MEDLINE

مواضيع طبية MeSH: Prostatic Neoplasms*/pathology, Male ; Humans ; Estradiol ; Androgen Antagonists/therapeutic use ; Androgens ; Quality of Life ; Estrogens ; Testosterone